We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Impax has counter-sued Shire Pharmaceuticals, which in October launched the latest in a string of patent infringement lawsuits against Impax over its plans to launch a generic version of Shire’s attention deficit hyperactivity disorder (ADHD) drug Adderall XR.